279 related articles for article (PubMed ID: 12439856)
41. Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe.
Matsuo M; Masumura T; Nishio H; Nakajima T; Kitoh Y; Takumi T; Koga J; Nakamura H
J Clin Invest; 1991 Jun; 87(6):2127-31. PubMed ID: 2040695
[TBL] [Abstract][Full Text] [Related]
42. Antisense oligonucleotide induced dystrophin exon 45 skipping at a low half-maximal effective concentration in a cell-free splicing system.
Malueka RG; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
Nucleic Acid Ther; 2011 Oct; 21(5):347-53. PubMed ID: 21967521
[TBL] [Abstract][Full Text] [Related]
43. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
[TBL] [Abstract][Full Text] [Related]
44. Splicing intervention for Duchenne muscular dystrophy.
McClorey G; Fletcher S; Wilton S
Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
[TBL] [Abstract][Full Text] [Related]
45. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy.
Shiga N; Takeshima Y; Sakamoto H; Inoue K; Yokota Y; Yokoyama M; Matsuo M
J Clin Invest; 1997 Nov; 100(9):2204-10. PubMed ID: 9410897
[TBL] [Abstract][Full Text] [Related]
46. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
47. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
[TBL] [Abstract][Full Text] [Related]
48. Insertion of a 5' truncated L1 element into the 3' end of exon 44 of the dystrophin gene resulted in skipping of the exon during splicing in a case of Duchenne muscular dystrophy.
Narita N; Nishio H; Kitoh Y; Ishikawa Y; Ishikawa Y; Minami R; Nakamura H; Matsuo M
J Clin Invest; 1993 May; 91(5):1862-7. PubMed ID: 8387534
[TBL] [Abstract][Full Text] [Related]
49. Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development.
Wu B; Benrashid E; Lu P; Cloer C; Zillmer A; Shaban M; Lu QL
PLoS One; 2011; 6(5):e19906. PubMed ID: 21611204
[TBL] [Abstract][Full Text] [Related]
50. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping.
Wein N; Avril A; Bartoli M; Beley C; Chaouch S; Laforêt P; Behin A; Butler-Browne G; Mouly V; Krahn M; Garcia L; Lévy N
Hum Mutat; 2010 Feb; 31(2):136-42. PubMed ID: 19953532
[TBL] [Abstract][Full Text] [Related]
51. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.
Alter J; Lou F; Rabinowitz A; Yin H; Rosenfeld J; Wilton SD; Partridge TA; Lu QL
Nat Med; 2006 Feb; 12(2):175-7. PubMed ID: 16444267
[TBL] [Abstract][Full Text] [Related]
52. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.
Bartlett RJ; Stockinger S; Denis MM; Bartlett WT; Inverardi L; Le TT; thi Man N; Morris GE; Bogan DJ; Metcalf-Bogan J; Kornegay JN
Nat Biotechnol; 2000 Jun; 18(6):615-22. PubMed ID: 10835598
[TBL] [Abstract][Full Text] [Related]
53. Microwave irradiation enhances gene and oligonucleotide delivery and induces effective exon skipping in myoblasts.
Doran TJ; Lu PJ; Vanier GS; Collins MJ; Wu B; Lu QL
Gene Ther; 2009 Jan; 16(1):119-26. PubMed ID: 18784750
[TBL] [Abstract][Full Text] [Related]
54. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides.
Dunckley MG; Manoharan M; Villiet P; Eperon IC; Dickson G
Hum Mol Genet; 1998 Jul; 7(7):1083-90. PubMed ID: 9618164
[TBL] [Abstract][Full Text] [Related]
55. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
[TBL] [Abstract][Full Text] [Related]
56. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
Aoki Y; Nakamura A; Yokota T; Saito T; Okazawa H; Nagata T; Takeda S
Mol Ther; 2010 Nov; 18(11):1995-2005. PubMed ID: 20823833
[TBL] [Abstract][Full Text] [Related]
57. Renadirsen, a Novel 2'OMeRNA/ENA
Ito K; Takakusa H; Kakuta M; Kanda A; Takagi N; Nagase H; Watanabe N; Asano D; Goda R; Masuda T; Nakamura A; Onishi Y; Onoda T; Koizumi M; Takeshima Y; Matsuo M; Takaishi K
Curr Issues Mol Biol; 2021 Sep; 43(3):1267-1281. PubMed ID: 34698059
[TBL] [Abstract][Full Text] [Related]
58. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.
Lu-Nguyen N; Dickson G; Malerba A
Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552
[TBL] [Abstract][Full Text] [Related]
59. Induction of revertant fibres in the mdx mouse using antisense oligonucleotides.
Fall AM; Johnsen R; Honeyman K; Iversen P; Fletcher S; Wilton SD
Genet Vaccines Ther; 2006 May; 4():3. PubMed ID: 16719929
[TBL] [Abstract][Full Text] [Related]
60. PCR analysis of dystrophin gene mutation and expression.
Chamberlain JS; Farwell NJ; Chamberlain JR; Cox GA; Caskey CT
J Cell Biochem; 1991 Jul; 46(3):255-9. PubMed ID: 1774226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
